ROCKVILLE, Md., Nov. 6, 2013 /PRNewswire-iReach/ -- ViGene Biosciences, Inc., a leading provider of viral gene-delivery systems, today announces the launch of its world's largest collection of premade human full-length cDNA ORF and miRNA adenoviruses. The collection features over 1,240 pre-packaged human miRNA precursor adenoviruses and 6,000 pre-packaged human full-length cDNA adenoviruses. Its introduction will significantly boost high throughput drug discovery, support functional genomic studies, and make life science research more efficient and cost-effective.
Recombinant adenoviruses are extremely efficient gene delivery systems that are widely used in human gene therapy and in vitro gene functional studies. Compared with lentiviral vector, transfection with adenovirus can reach 100% (vs. 30% with lentivirus), and protein expression can reach up to 10-20% of the total protein. Traditionally, adenoviral vector cloning and virus production requires up to 4-6 weeks, a complex and time-consuming process. The creation of this genome-wide premade adenoviruses collection that is readily available will benefit researchers who work with difficult-to-transfect primary cells and stem cells, as well as any other researchers who use full-length cDNA clones.
"Our strength is not only the innovative technology for adenoviral vector production, but also the capability to create the most comprehensive collection of human full-length cDNA clones in the world," said Dr. Ying Chen, Vice President of Research and Development of ViGene Biosciences, Inc. "The biotech industry has been depending heavily on the MGC (Mammalian Gene Collection) for full-length cDNA clones, but the MGC only contains 13,000 full-length cDNA clones. Of the 19,000 unique genes (loci) in the human genome, we have systematically generated 18,000 full-length cDNA templates representing 18000 unique loci. Each of these cDNAs will be cloned into our adenoviral vector to produce ready-to-use adenoviruses." noted Dr. Chen. "We are thrilled to have this near-complete genome-wide premade adenovirus collection. It will greatly accelerate genome-wide high throughput drug screening and development, cell-based assays, and many aspects of gene function studies."
In addition to the adenoviral vectors, ViGene has also developed lentiviral and adeno-associated viral (AAV) vectors. Upon completion of the genome-wide adenovirus production, ViGene is excited to further transfer the same set of full-length cDNA ORFs into lentiviral vector and AAV vector to create an even broader premade virus collection. ViGene's largest premade virus collection will represent the next generation gene products for advancing life science research.
About ViGene Biosciences
Based in Rockville, Maryland, ViGene Biosciences, Inc., is a genomics tool company that develops cutting-edge and next generation life science research reagents to support high-throughput drug discovery and functional genomics. Pioneering the development of quality adenovirus and other viral vector production, ViGene features the world's largest collection of human full-length cDNA ORF clones, miRNA clones, premade cDNA ORF and miRNA adenoviruses, and top-of-the-line custom services. ViGene is committed to its mission "Quality Is Our Business," for providing the highest quality products, services and bringing the most innovative ideas for gene based research.For more information, please visit www.vigenebio.com or contact ViGene by email at firstname.lastname@example.org or call (301)-231-0600
Media Contact: Kevin Lee, ViGene Biosciences, 301-231-0600, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ViGene Biosciences, Inc.